Roivant Sciences vs vTv Therapeutics
ROIV and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ROIV and VTVT compare
Roivant Sciences is the larger company, worth 367 times as much as vTv Therapeutics ($28.6B against $77.9M).
vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 102% for Roivant Sciences).
vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.8% compared with −838% at Roivant Sciences.
vTv Therapeutics scores higher on the StockData Score (11 against 8 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ROIV | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $28.6B | $77.9M |
| Share price | $39.53 | $19.69 |
| Change, 1 year | 85.4% | −36.5% |
| Change, 5 years | 394% | −65.3% |
| Beta (5Y) | 0.85 | 1.08 |
| Employees | 721 | 26 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 695× | 2.1× (better) |
| P/B | 7.1× | 1.1× (better) |
| FCF yield | −0.12% | – |
| Fair value | – | $40.43 |
| Margin of safety | – | 51.3% |
| Growth | ||
| Revenue growth (TTM) | 102% | 216600% (better) |
| Revenue growth, 5Y average | −19.1% | – |
| Profitability | ||
| Operating margin | −1358% | −29.8% (better) |
| Net margin | −838% | −20.8% (better) |
| FCF margin | −81.2% | – |
| Return on equity | −8.2% (better) | −11.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 15.56 (better) | 11.19 |
| Altman Z-score | 45.37 (better) | 0.51 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.1% | 40.6% |
| Held by insiders | 13.9% | 26.3% |
| Insider net buying, 12 months | −$798M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.3% | 5.0% |
Go deeper
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.